Fingolimod and HPV: What You Need to Know About This MS Drug
"Understanding the Link Between Fingolimod, HPV, and How to Protect Your Health"
Multiple sclerosis (MS) treatment has advanced significantly, with new medications offering hope. However, these therapies, known as disease-modifying therapies (DMTs), require continuous safety evaluation through studies and reports.
Fingolimod (Gilenya®), a sphingosine-1-phosphate receptor modulator, is widely used for relapsing-remitting MS, with over 255,000 patients treated worldwide. While effective, it's crucial to understand its potential side effects, especially concerning infections.
This article will break down a recent study that investigated cases of human papillomavirus (HPV)-related conditions in patients using fingolimod. We'll explore what this means for your health and how to stay proactive about your care.
Documented HPV Findings
A report of oral HPV-related epithelial proliferation during long-term fingolimod therapy identified low-risk HPV types 6 and 11 through DNA testing. The clinical presentation, histopathologic features, and laboratory findings were consistent with an HPV-related epithelial proliferation potentially associated with fingolimod use. A separate 2026 review notes that HPV vaccination is preventive, may be less immunogenic during therapy, and that prospective studies are needed to define incidence, risk predictors, and vaccine effectiveness in fingolimod-treated populations.
Evidence And Uncertainty
Cutaneous warts associated with HPV have raised concern about other HPV-driven conditions, including cervical cancer, in people receiving fingolimod. An abstract describing five patients treated with fingolimod who developed HPV-associated cervical and anogenital cancers suggested a possible link. However, the available report states that there were no data confirming a connection between fingolimod and HPV-related dysplasia.
Early Clinical Reports
A case report of oral HPV-related epithelial proliferation favored a diagnosis associated with fingolimod based on histopathologic features, additional HPV testing, and the context of long-term immunosuppressive therapy. Another report described three cases of viral skin infections related to fingolimod therapy in people with relapsing-remitting multiple sclerosis. One of those cases involved cervical dysplasia.
Decoding the Fingolimod and HPV Connection: What the Research Says
A recent study published in Multiple Sclerosis Journal (MSJ) shed light on a potential link between fingolimod treatment and HPV-related issues. The study highlighted five cases of human papillomavirus (HPV)-related warts in patients treated with fingolimod for 17–58 months.
- Weakened Immune Surveillance: Fingolimod may reduce the body's ability to detect and fight off viral oncogenesis (the process by which viruses can cause cancer).
- Viral-Associated Malignancies: There have been reports of viral-associated malignancies in fingolimod users, including HPV-related vulvar and cervical dysplasia, and squamous cell carcinoma of the tonsils.
Current Research
A 2026 case report and literature review states that fingolimod has been associated with an increased risk of HPV-related mucocutaneous lesions because of its immunosuppressive effects. A 2018 clinical commentary addressed the report titled “Warts and all: Fingolimod and unusual HPV associated lesions.” More recent pharmacovigilance research in women with multiple sclerosis used WHO VigiBase data and calculated adjusted reporting odds ratios and Bayesian information components, with 95% confidence intervals, for HPV-related conditions associated with each MS disease-modifying therapy.
Case-Based Perspective
A published case report describes a woman diagnosed with relapsing-remitting multiple sclerosis. The report presents fingolimod as a new option for multiple sclerosis in that case. The supplied source does not provide comparative HPV outcomes, numerical effectiveness data, or direct comparisons with other treatments.
Protecting Your Health: Practical Steps for Patients on Fingolimod
While these findings are concerning, they shouldn't cause panic. Instead, they highlight the importance of proactive health management. If you're taking fingolimod, here are steps you can take:
An Eight-Year Treatment Experience
The first documented case of oral mucosal HPV-related epithelial proliferation during long-term fingolimod therapy involved a 36-year-old man. He had multiple mildly papillomatous gingival lesions while receiving Gilenya therapy. The treatment duration reported in the case was eight years.